Group 1 - The company announced a capital increase agreement and a share transfer agreement with an industry partner, involving a total payment of RMB 2 billion for acquiring 80% of the shares in a subsidiary focused on cardiovascular drug development [1][2] - After the completion of the transaction, the ownership structure will be: Beijing Jakesi will hold 10%, Haisong Capital will hold 80%, and the industry partner will hold 10% of the shares in the subsidiary [1] - The subsidiary, Jakesi Ruikang, is primarily engaged in the internal research and development of cardiovascular disease treatment drugs and holds intellectual property related to early-stage cardiovascular research and development projects [1] Group 2 - The company is focused on developing innovative oncology products and solutions to improve health outcomes, aligning with its strategic development in key cancer pipeline products [2] - The proceeds from the share transfer will be used for the research, production, and commercialization of the company's Pan-KRAS inhibitors and other innovative oncology projects [2] - The transaction aims to optimize capital allocation and enhance organizational efficiency while maintaining future value through a risk-sharing model [2]
加科思-B：北京加科思拟透过增资协议及股权转让协议出售加科瑞康90%股权